Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder

• Main Authors: Greenberg J, Palmer JB, Chan WW, Correia CE, Whalley D, Shannon P, Sawicki GS
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-10-01
• Series: Patient Preference and Adherence
• Subjects: Cystic fibrosis; patient satisfaction; tobramycin; dry powder inhalers.
• Online Access: https://www.dovepress.com/treatment-satisfaction-in-cystic-fibrosis-early-patient-experience-wit-peer-reviewed-article-PPA

Jonathan Greenberg,1 Jacqueline B Palmer,2 Wing W Chan,2 Catherine E Correia,1 Diane Whalley,3 Paul Shannon,3 Gregory S Sawicki1 1Division of Respiratory Diseases, Boston Children’s Hospital, Boston, MA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3RTI Health Solutions, Manchester, UK Background: This study assessed treatment satisfaction of cystic fibrosis (CF) patients in a routine clinical setting for tobramycin inhalation powder (TIP), the first dry powder–inhaled antibiotic for Pseudomonas aeruginosa infection.Methods: CF patients aged 6 years or older treated with at least one cycle of TIP completed a web survey on experience with TIP, including the Treatment Satisfaction Questionnaire for Medication (TSQM). Regression analysis determined the factors associated with TSQM global satisfaction. Results: Eighty patients (mean age ± standard deviation: 24.4±9.4 years; 57.5% female; mean forced expiratory volume in 1 second ± standard deviation: 67.1%±27.3% predicted) completed the survey. The majority expressed satisfaction with TIP’s administration time (100%), time to clean (97.1%), portability (97.1%), and ease of use (94.3%). Effectiveness was significantly associated with TSQM global satisfaction (regression R-squared: 0.54). Conclusion: Patient preferences for TIP were based on administration time and ease of use. Global satisfaction was related to greater patient-perceived effectiveness. Keywords: cystic fibrosis, patient satisfaction, tobramycin, dry powder inhalers